I am excited to share that BrightInsight formally announced our global partnership with AstraZeneca to build and manage AstraZeneca’s digital health solutions at scale while maintaining compliance with privacy, security and regulatory requirements.
Given the current state of the world and focus on COVID-19, we seriously considered whether or not to make this announcement. We ultimately decided to share the news to rally our own employees around our progress and to shine a spotlight on digital health.
We believe that digital health represents a major opportunity to alleviate some of the biggest concerns in healthcare today, including the length and cost of clinical trials and the burden on traditional healthcare settings. Digital health solutions will build more resilience into our healthcare system, enabling us to tackle expected and unexpected challenges in the future. As the underlying technology platform for hosting regulated digital health solutions, BrightInsight will be fundamental in digital health scaling globally.
That being said, we want to take the time to recognize this company milestone and share a little more about the partnership:
- AstraZeneca will develop apps, algorithms, Software as a Medical Device and connected devices on top of our BrightInsight Platform that enhance and personalize care while making overall healthcare delivery more efficient for patients and providers.
- The first major program we are working on together is in the chronic disease management space.
- We have shared research on how BrightInsight’s robust functionality facilitates lower costs and accelerates time to market when compared to building a custom platform from scratch. AstraZeneca recognized this and quickly dismissed the concept of building their own platform so they could focus instead on developing transformational digital health solutions to improve patient outcomes.
“We selected BrightInsight because its pre-built, compliant platform accelerates our time to market while allowing us to focus on digital health innovation and leveraging our clinical know-how to improve patient outcomes instead of the underlying infrastructure,” said Karan Arora, Chief Commercial Digital Officer and Global Vice President, AstraZeneca.
From our code to culture, we are committed to supporting regulated digital health solutions across therapeutic areas, and are honored to add AstraZeneca to our growing list of top tier biopharma customers.
We look forward to sharing more specifics on our collaboration in the coming months.